Pasithea Therapeutics Email Format
Pharmaceutical ManufacturingFlorida, United States11-50 Employees
Pasithea Therapeutics is a biotechnology company focused on discovering and developing treatments for central nervous system disorders. It builds on neuroscience, medicinal chemistry, and translational medicine to create new molecular entities that address the pathophysiology of CNS diseases, with the goal of delivering therapies to patients. The company is based in Miami, Florida, and operates within the pharmaceutical manufacturing sector, pursuing clinical-stage research programs. Its pipeline includes PAS-004, described as a next-generation macrocyclic MEK inhibitor, illustrating a focus on CNS-targeted therapeutic approaches. In May 2026, Pasithea named Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer, effective May 1, 2026. The firm participates in industry events and maintains a presence in the broader life sciences community as it advances its CNS-focused programs.